Strides runs up 7% post successful USFDA plant inspection

Shares of drug firm Strides Shasun surged nearly 7 per cent today after the US health regulator completed a successful inspection of the company's oral dosage facility in Bengaluru without any adverse observations.
The stock soared 6.77 per cent to Rs 1,205 on BSE.
On NSE, shares of the company climbed 6.74 per cent to Rs 1,205.
The United States Food and Drug Administration (USFDA) has completed the inspection of the company's oral dosage facility in Bengaluru with 'Zero 483s', Strides Shasun had yesterday said in a filing to BSE.
With the recently-closed Establishment Inspection Report (EIR), the entire facility is now USFDA-compliant, it added.

"The audit was carried out related to a product filed from the new semi solids block from where the company has made a series of filings," Strides Shasun said.
The Bengaluru facility manufactures oral dosage forms, including tablets, capsules, ointments and liquids.
The plant supports current and future submissions for the US market, Strides Shasun said.